Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
FDA rejects Novartis’ cholesterol drug after factory inspection issueNovartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster Share XFDA rejects Novartis’ cholesterol drug after factory inspection issuehttps://pharmaphorum.com/news/fda-rejects-novartis-cholesterol-drug-after-missed-factory-inspection/
Entresto set for big sales hike after FDA panel endorsementNovartis’ Entresto is on course to become the first drug to be approved in the US for a Share XEntresto set for big sales hike after FDA panel endorsementhttps://pharmaphorum.com/news/entresto-set-for-big-sales-hike-after-fda-panel-endorsement/
Amgen shares down as heart failure drug disappoints in phase 3 trialShares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug Share XAmgen shares down as heart failure drug disappoints in phase 3 trialhttps://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/
RHYTHM AI cleared for large trial of atrial fibrillation mapping toolUK-based RHYTHM AI is to go ahead with a larger clinical trial of its artificial intelligence (AI)-driven system, Share XRHYTHM AI cleared for large trial of atrial fibrillation mapping toolhttps://pharmaphorum.com/news/rhythm-ai-cleared-for-large-trial-of-atrial-fibrillation-mapping-tool/
Regeneron’s cholesterol drug evinacumab claims February FDA dateThe FDA has started a speedy review of Regeneron’s ANGPTL3-targeting antibody evinacumab for a rare, inherited disorder that Share XRegeneron’s cholesterol drug evinacumab claims February FDA datehttps://pharmaphorum.com/news/regenerons-cholesterol-drug-evinacumab-claims-february-fda-date/
AZ picks up $350m after selling hypertension drugsAstraZeneca has picked up a $350m windfall after selling off five hypertension medicines to generics specialist Atnahs Pharma. Share XAZ picks up $350m after selling hypertension drugshttps://pharmaphorum.com/news/az-picks-up-350m-after-selling-hypertension-drugs/
FDA approves Caption Health’s AI-driven cardiac ultrasound softwareThe FDA has approved software from medical artificial intelligence (AI) firm Caption Health, that allows medical professionals without Share XFDA approves Caption Health’s AI-driven cardiac ultrasound softwarehttps://pharmaphorum.com/news/fda-approves-caption-healths-ai-driven-cardiac-imaging-software/
NICE backs Medtronic’s AF monitor in post-stroke patientsEngland’s NHS could prevent hundreds of strokes of unknown cause with a new implantable monitor that transmits data Share XNICE backs Medtronic’s AF monitor in post-stroke patientshttps://pharmaphorum.com/news/nice-backs-medtronics-af-monitor-in-post-stroke-patients/
